For Adults 18+
First Line Agents-Long Acting Psychostimulant:
*CADDRA is the Canadian ADHD Resource Alliance organization.

Second Line/Adjunctive Agents-Short Acting and Intermediate Acting Psychostimulants:

Second Line/Adjunctive Agent-Long Acting Non Psychostimulant-Selective Norepinephrine Reuptake Inhibitor:

Off-Label Treatment for ADHD:

General Information:
– All ADHD medications have effects on the cardiovascular system-increase heart rate and blood pressure.
– Start with a very low dose, stop when target symptoms are better.
– Long-acting medication is preferable to short-acting as improve compliance and have better effects.
– While long-acting medication is preferred they can be augmented with short-acting psychostimulants
– Monitor patients every 2 weeks until correct dose is reached then every 3 months thereafter.

References
https://pdf.hres.ca/dpd_pm/00032076.PDF
https://purdue.ca/wp-content/uploads/2020/02/Biphentin-PM-EN-Jan2020.pdf
https://pdf.hres.ca/dpd_pm/00042338.PDF
https://www.caddra.ca/wp-content/uploads/FOQUEST-Product-Monograph-E-01Mar2019.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf
https://pdf.hres.ca/dpd_pm/00044605.PDF
https://www.ask.novartispharma.ca/download.htm?res=ritalin_scrip_e.pdf&resTitleId=748
https://pi.lilly.com/ca/strattera-ca-pm.pdf
http://www.auropharma.ca/products/monograph/Auro-Modafinil-PM.pdf